Compare Crispr Therapeutics AG (CRSP) vs Jabil Inc (JBL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Jabil Inc — how do they compare? Crispr Therapeutics AG trades at $50.05 (market cap $4.97B), while Jabil Inc trades at $327.45 (market cap $34.25B). The key difference: Jabil Inc is far larger — about 6.9× Crispr Therapeutics AG's market cap, and Jabil Inc pays a 0.1% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | JBL | |
|---|---|---|
Market Cap | $4.97B | $34.25B |
Sector | Health | Technology |
52-Week High | $76.78 | $385.50 |
52-Week Low | $44.34 | $192.49 |
Enterprise Value | $3.32B | $36.78B |
Dividend Yield | — | 0.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
JBL trades at $321.96, down 2.52% today, with a bearish technical signal but strong fundamental momentum. Recent quarters show consistent earnings beats, with Q1 2026 EPS of $3.16 exceeding the $3.10 estimate. Revenue growth is robust, projected to rise from $29.80B in 2025 to $33.60B in 2026, driven by AI infrastructure demand. The stock faces near-term pressure but maintains a 50% buy rating from analysts, with a consensus price target of $436.50 suggesting significant upside potential from current levels.
JBL's outlook is supported by AI-driven expansion and solid earnings, but high valuation multiples like a P/E of 40.9 pose risks if growth slows. Competitive pressures in electronics manufacturing and macroeconomic volatility could impact margins. Investors should weigh the strong analyst consensus against technical bearish signals and elevated valuation before committing capital.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Jabil Inc
Jabil is a global manufacturing solutions provider for industries including healthcare, automotive, and cloud. It offers comprehensive design, engineering, and supply chain management for complex electronic products.
Read more on JBL →
